| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/22/2007 | CN101019648A Health product for reducing blood pressure |
| 08/22/2007 | CN101019647A Health product for reducing blood pressure |
| 08/22/2007 | CN101019645A Health food for remitting fatigue and raising hypoxia tolerance and its prepn |
| 08/21/2007 | US7259271 [4-(tert-butyldimethylsilanyloxy)-3-oxobutyl]methylcarbamic acid tert-butyl ester; (R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-amine; for the treatment of cardiovascular disorders such as hypertension and chronic heart failure |
| 08/21/2007 | US7259233 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 08/21/2007 | US7259181 β crystalline form of perindopril tert-butylamine salt |
| 08/21/2007 | US7259177 Containing an oxazole ring 2-phenyl-, furanyl- or thiophenyl-substituted; e.g., 2,2-Dimethyl-4-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-butyric acid; treating disorders of fatty acid metabolism, glucose utilization disorders, and also of disorders in which insulin resistance is involvolved |
| 08/21/2007 | US7259175 Alkanoic acids substituted with a group containing pyridinyl-, pyrimidinyl- or pyrazinyl-phenyl linked through a thiazolyl- or oxazolyl- phenyl group; e.g., 3-[4-(2-{2-[6-(2-Fluoro-phenyl)-pyridin-3-yl]-5-methyl-thiazol-4-yl}-ethoxy)-2-methyl-phenyl]-propionic acid; treating diabetes and atherosclerosis |
| 08/21/2007 | US7259171 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
| 08/21/2007 | US7259168 2-Aminoalkyl-thieno[2,3-d]pyrimidines |
| 08/21/2007 | US7259162 Benzazole derivatives and their use as JNK modulators |
| 08/21/2007 | US7259161 For therapy of immune response, an autoimmune disease, a neurodegenerative, or a solid or hematologic malignancy |
| 08/21/2007 | US7259159 Vitronectin receptor antagonists for treating and preventing osteoporosis, bone disorders |
| 08/21/2007 | US7259157 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
| 08/21/2007 | US7259154 Pyrrolopyrimidines |
| 08/21/2007 | US7259149 Enhancing the transfection efficiency in treating critical limb ischemia of naked plasmid DNA that encodes hepatocyte growth factor and that is operably linked to a promoter by injecting the DNA directly into the ischemic muscle in combination with hyperbaric oxygen therapy |
| 08/21/2007 | US7258872 Chromone enteric release formulation |
| 08/21/2007 | US7258855 Culturing a transformant in a medium, allowing the polypeptide having phospholipase a2 activity fo form and accumulating in the culture, recovering the polypeptide thus formed |
| 08/21/2007 | CA2328730C Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| 08/21/2007 | CA2294036C Polyallylamine polymers for treating hypercholesterolemia |
| 08/21/2007 | CA2165995C Medicaments for the treatment of restenosis and arterial sclerosis |
| 08/16/2007 | WO2007092469A2 Combination of organic compounds |
| 08/16/2007 | WO2007092270A2 Combination therapy for coronary artery disease |
| 08/16/2007 | WO2007090793A1 Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists |
| 08/16/2007 | WO2007090750A1 Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating cetp-mediated disorders |
| 08/16/2007 | WO2007090733A1 Nitrooxy derivatives suitable as alpha2 adrenergic receptor agonists |
| 08/16/2007 | WO2007076086A3 Tricyclic spiro compounds useful as transforming growth factor modulators |
| 08/16/2007 | WO2007076053A3 Stable s-nitrosothiol formulations |
| 08/16/2007 | WO2007068948A3 Pharmaceutical sustained release compositions comprising in particular thyroid hormones |
| 08/16/2007 | WO2007047969A3 Methods of decreasing vascular calcification using il-1 inhibitors |
| 08/16/2007 | WO2007009589A3 Use of soluble guanylate cyclase for the treatment of raynaud's phenomenon |
| 08/16/2007 | WO2007000292A3 Novel targets and compounds useful in the treatment and/or prophylaxis of a cardiovascular disorder, dyslipidemia and atherosclerosis, and methods to identify such compounds |
| 08/16/2007 | WO2006124753A3 Antipyretic agents against vr1-antagonist-induced increases in body temperature |
| 08/16/2007 | WO2006121684A3 Acyl hydrazones for treating cardiovascular diseases |
| 08/16/2007 | WO2005037260A3 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms |
| 08/16/2007 | WO2004007437A9 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 08/16/2007 | WO2003031404A3 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 08/16/2007 | US20070191592 amidated peptide; stress-related conditions |
| 08/16/2007 | US20070191478 Methods of treating cardio pulmonary diseases with NO group compounds |
| 08/16/2007 | US20070191465 Channel blocking compounds |
| 08/16/2007 | US20070191435 Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 08/16/2007 | US20070191419 (6R,8S)-6-(spiro[isobenzofuran-1-(3H), 4'-piperidin]-1'-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-ol), exhibiting an antagonism to binding of nociceptin to opioid receptor-like-1 receptors, useful as medicines for diseases associated with pain and appetite control or memory and learning |
| 08/16/2007 | US20070191392 Dipeptide nitrile cathespin k inhibitors |
| 08/16/2007 | US20070191390 Substituted heterocyclic compounds |
| 08/16/2007 | US20070191386 Bicyclo-pyrazole compounds specially pyrrolo[3,4-c]pyrazole or tetrahydropyridine[4,3-c]pyrazole derivatives; anticarcinogenic agents; N-{5-phenylacetyl-4,6-dihydropyrrolo[3,4-c]pyrazol-3-yl}phenylacetamide; modulators of apoptosis; combinatorial chemical library with an isocyanate polystyrenic resin |
| 08/16/2007 | US20070191347 Substituted sulfonamides and ureas useful for inhibiting kinase activity |
| 08/16/2007 | US20070191328 Isoquinoline compounds |
| 08/16/2007 | US20070191320 Methods of treatment for female sexual arousal disorder |
| 08/16/2007 | US20070191289 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 08/16/2007 | US20070190634 Compositions useful as inhibitors of protein kinases |
| 08/16/2007 | US20070190612 31 Human Secreted Proteins |
| 08/16/2007 | US20070190576 Mitogenic oxygenase regulators |
| 08/16/2007 | US20070190106 Phosphorus-containing compounds & uses thereof |
| 08/16/2007 | US20070190041 Novel benzothiazepine and bensothiepine compounds |
| 08/16/2007 | US20070190021 Poly(diallylamine)-based bile acid sequestrants |
| 08/16/2007 | DE102006006588A1 Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung Quick-release irbesartan-containing pharmaceutical composition |
| 08/16/2007 | CA2641501A1 Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists |
| 08/16/2007 | CA2640662A1 Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating cetp-mediated disorders |
| 08/16/2007 | CA2637792A1 Combination of organic compounds |
| 08/16/2007 | CA2627900A1 Compounds and compositions as lxr modulators |
| 08/15/2007 | EP1818329A1 (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate |
| 08/15/2007 | EP1818326A1 Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds |
| 08/15/2007 | EP1818325A2 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| 08/15/2007 | EP1818063A1 Medicine for treatment of disease caused by hyperstimulatory cytotoxicity and therapeutic method |
| 08/15/2007 | EP1818056A1 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 08/15/2007 | EP1818052A1 Use of formoterol in the prophylactic and/or therapeutic treatment of muscle wasting and/or cachectic syndrome which are associated with catabolic conditions of certain diseases, such as cancer, aids, infections, diabetes and others |
| 08/15/2007 | EP1818008A1 Noninvasive measurements of chemical substances |
| 08/15/2007 | EP1817288A1 Dual antiplatelet/anticoagulant pyridoxine analogs |
| 08/15/2007 | EP1817036A2 Modulators of muscarinic receptors |
| 08/15/2007 | EP1817027A2 Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| 08/15/2007 | EP1816912A2 Treatment of stroke with histamine h3 inverse agonists or histamine h3 antagonists |
| 08/15/2007 | EP1718641B1 Benzimidazole derivative and its use as a ii receptor antagonist |
| 08/15/2007 | EP1673092B1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 08/15/2007 | EP1554280B1 Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
| 08/15/2007 | EP1490371B1 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same |
| 08/15/2007 | EP1480640B1 Peroxisome proliferator activated receptor modulators |
| 08/15/2007 | EP1471886B1 Method for increasing the water-solubility of lipophilic, active substances, production of highly concentrated aqueous compositions of said active substances, corresponding products and their use |
| 08/15/2007 | EP1451196B1 The use of substituted tetracyclic imidazole derivatives as anti-histaminics |
| 08/15/2007 | EP1442023B1 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 08/15/2007 | EP1385825B1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives |
| 08/15/2007 | EP1363668B1 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/15/2007 | EP1355588B1 Device for delivery of therepeutic agents |
| 08/15/2007 | EP1343488B1 Treatment of statin side effects |
| 08/15/2007 | EP1339458B1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 08/15/2007 | EP1294439B1 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system |
| 08/15/2007 | EP1292568B1 Benzamide ligands for the thyroid receptor |
| 08/15/2007 | EP1254251B1 Neurosteroids as markers for alzheimer's disease |
| 08/15/2007 | EP1232251B1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| 08/15/2007 | EP1187628B1 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 08/15/2007 | CN1331882C Peptide of decreasing blood pressure of protein of acetes chinensis, preparing method and application |
| 08/15/2007 | CN1331862C Di-aryl acid derivatives as PPAR receptor ligands |
| 08/15/2007 | CN1331848C Tricyclic steroid hormone nuclear receptor modulators |
| 08/15/2007 | CN1331533C Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy |
| 08/15/2007 | CN1331505C Medicament for the rehabilitation of the cardio - cerebral vascular diseases and the treatment of bone pain disease and its preparation method |
| 08/15/2007 | CN1331491C Ginseng and aconite transfusion for treating qi vacuity and yang desertion and its preparation method |
| 08/15/2007 | CN1331487C Chinese patent medicine for hemorrhoid and its preparation |
| 08/15/2007 | CN1331486C Use of azalea as medicine for cardiac diseases |
| 08/15/2007 | CN1331484C Extractive of Chinese traditional medicine prepared from epimedium and drynaria, and method for producing preparation |
| 08/15/2007 | CN1331476C Method for preparing coenzyme-A sublingual lozenge |
| 08/15/2007 | CN1331473C Application of 20(S)-ginsenoside-Rg [3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease |